AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28755256 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision or watch and wait policy for patients with cCR
Number of subjects: 0
Study 28755389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 2.0 mg for 6 months
Number of subjects: 1
Study 28755389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide therapy
Number of subjects: 1
Study 28755782 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg once monthly)
Number of subjects: 436
Study 28755782 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide (20 μg once daily)
Number of subjects: 436
Study 28755782 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab
Number of subjects: 436
Study 28755782 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 436
Study 28755959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical CG0070
Number of subjects: 45
Study 28756065 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg/d
Number of subjects: 257
Study 28756065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 28756183 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (vitamin K2) supplementation (360 μg once daily) for 8 weeks
Number of subjects: 60
Study 28757156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty (BT)
Number of subjects: 0
Study 28757639 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 56
Study 28757639 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 56
Study 28758370 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Food Photography Method (RFPM)
Number of subjects: 39
Study 28758370 — intervention group
Group type: COMPARATOR
Intervention: Doubly Labeled Water (DLW) method
Number of subjects: 39
Study 28759304 — intervention group
Group type: EXPERIMENTAL
Intervention: Third molar extraction
Number of subjects: 40
Study 28759304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no third molars)
Number of subjects: 40
Study 28760151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation (14 preoperative sessions and 39 postoperative sessions)
Number of subjects: 140
Study 28760151 — intervention group
Group type: COMPARATOR
Intervention: Standard care (one educational session and early inpatient postoperative physiotherapy)
Number of subjects: 140
Study 28760152 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 maintenance therapy
Number of subjects: 0
Study 28760152 — intervention group
Group type: COMPARATOR
Intervention: Continuation of the same regimen as during the primary period
Number of subjects: 0
Study 28760533 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperemia score
Number of subjects: 58
Study 28760533 — intervention group
Group type: EXPERIMENTAL
Intervention: Tsuga score
Number of subjects: 58
Study 28760541 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for insomnia
Number of subjects: 0
Study 28760669 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant BFL-associated proteins (IGLL1)
Number of subjects: 55
Study 28760669 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant BFL-associated proteins (ProE)
Number of subjects: 55
Study 28760669 — intervention group
Group type: COMPARATOR
Intervention: Precipitin assays with pigeon dropping extracts
Number of subjects: 55
Study 28760834 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicator score for advance care planning
Number of subjects: 506
Study 28760834 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicator score for goals-of-care discussions
Number of subjects: 506
Study 28760834 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality indicator score
Number of subjects: 506
Study 28761384 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 463
Study 28761384 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 463
Study 28761581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg guaifenesin/120 mg pseudoephedrine hydrochloride extended-release, bilayer tablets for 7 consecutive days
Number of subjects: 1179
Study 28761581 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 consecutive days
Number of subjects: 1179
Study 28761581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg guaifenesin/120 mg pseudoephedrine hydrochloride extended-release
Number of subjects: 1179
Study 28761581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1179
Study 28761651 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting during Ramadan
Number of subjects: 53
Study 28761651 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adjusted medication during fasting
Number of subjects: 53
Study 28761651 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet management during fasting
Number of subjects: 53
Study 28761651 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with religious authorities
Number of subjects: 53
Study 28761660 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH dietary pattern (DASH score)
Number of subjects: 15942
Study 28761662 — intervention group
Group type: EXPERIMENTAL
Intervention: Two eggs/day
Number of subjects: 34
Study 28761662 — intervention group
Group type: COMPARATOR
Intervention: Egg exclusion
Number of subjects: 34
Study 28761675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624
Study 28761675 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study 28761678 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stent (PF-SES)
Number of subjects: 2877
Study 28761685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-therapy stent
Number of subjects: 1000
Study 28761697 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention program (strenuous physical exercise)
Number of subjects: 75
Study 28761699 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel exercise (n=9)
Number of subjects: 25
Study 28761699 — intervention group
Group type: COMPARATOR
Intervention: Inactive group (n=16)
Number of subjects: 25
Study 28761750 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept in combination with FOLFIRI (infusional fluorouracil, leucovorin and irinotecan)
Number of subjects: 1226
Study 28761750 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with FOLFIRI (infusional fluorouracil, leucovorin and irinotecan)
Number of subjects: 1226
Study 28761750 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 1226
Study 28762099 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary childhood obesity treatment programme
Number of subjects: 1291
Study 28762099 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BMI SDS (n=315)
Number of subjects: 1291
Study 28763344 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50-100 mg/day for 8 weeks
Number of subjects: 35
Study 28764748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib (150 mg/m) in combination with weekly trastuzumab (2 mg/kg) and paclitaxel (80 mg/m)
Number of subjects: 9
Study 28764748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib (150 mg/m)
Number of subjects: 9
Study 28764836 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term aspirin treatment cessation before surgery
Number of subjects: 805
Study 28764836 — intervention group
Group type: COMPARATOR
Intervention: Prior PCI with stent implantation
Number of subjects: 805
Study 28764836 — intervention group
Group type: COMPARATOR
Intervention: Previous discontinuation of aspirin treatment
Number of subjects: 805
Study 28764836 — intervention group
Group type: COMPARATOR
Intervention: Risk of bleeding into a closed space
Number of subjects: 805
Study 28764836 — intervention group
Group type: COMPARATOR
Intervention: Unawareness of the reason for aspirin use
Number of subjects: 805
Study 28764836 — intervention group
Group type: COMPARATOR
Intervention: Preoperative consultation with anesthesiologist <2 days before surgery
Number of subjects: 805
Study 28765146 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg Spectralis spectral domain-optical coherence tomography (SD-OCT) device
Number of subjects: 32
Study 28765146 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg Spectralis OCT
Number of subjects: 32
Study 28765146 — intervention group
Group type: EXPERIMENTAL
Intervention: SD-OCT/SLO imaging
Number of subjects: 32
Study 28765502 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant 5-fluorouracil (5-FU) 225 mg/m², oxaliplatin, and lapatinib in combination with radiation therapy
Number of subjects: 12
Study 28765502 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant 5-fluorouracil (5-FU) in combination with radiation therapy
Number of subjects: 12
Study 28766094 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum illnesses (including uterine prolapse, urinary tract infection, stress related incontinence, headache, convulsions, night blindness, anemia, pneumonia, gastroenteritis, hepatobiliary disease)
Number of subjects: 39000
Study 28766267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass (GBP)
Number of subjects: 4047
Study 28766267 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical banded gastroplasty (VBG)
Number of subjects: 4047
Study 28766267 — intervention group
Group type: COMPARATOR
Intervention: Obese non-operated controls (OB-controls)
Number of subjects: 4047
Study 28766267 — intervention group
Group type: COMPARATOR
Intervention: MONICA-controls
Number of subjects: 4047
Study 28766459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Difficulties Scale (CDS) total score
Number of subjects: 95
Study 28766459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Difficulties Scale (CDS) praxis subscale
Number of subjects: 95
Study 28766535 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL-2009 protocol (non-intensive, continuous cytotoxic treatment)
Number of subjects: 194
Study 28766535 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL-2009 protocol
Number of subjects: 194
Study 28767349 — intervention group
Group type: EXPERIMENTAL
Intervention: IdeS
Number of subjects: 25
Study 28767456 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous regional anaesthesia (epidural or peripheral nerve block)
Number of subjects: 563
Study 28767456 — intervention group
Group type: COMPARATOR
Intervention: Single shot peripheral nerve block
Number of subjects: 563
Study 28767456 — intervention group
Group type: COMPARATOR
Intervention: No regional anaesthesia
Number of subjects: 563
Study 28767456 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 563
Study 28767456 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous regional anaesthesia
Number of subjects: 563
Study 28767456 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher NRS score at 1 month, younger age, history of anxiety or depression, pro-inflammatory status, higher BMI, lower ASA physical status
Number of subjects: 563
Study 28767463 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoma bulk (≥10 mm, 4th quartile)
Number of subjects: 1948
Study 28767463 — intervention group
Group type: COMPARATOR
Intervention: Conventional paradigm (high-risk baseline findings: ≥3 adenomas, large adenomas (≥1 cm), or adenomas with villous components or high-grade dysplasia)
Number of subjects: 1948
Study 28767463 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoma bulk (as a continuous variable)
Number of subjects: 1948
Study 28768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 71
Study 28768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep diary
Number of subjects: 71
Study 28768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy
Number of subjects: 71
Study 28768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnographic nap
Number of subjects: 71
Study 28768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sleep problems
Number of subjects: 71
Study 28768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypersomnia conditions
Number of subjects: 71
Study 28768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) risk
Number of subjects: 71
Study 28768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Restless legs syndrome
Number of subjects: 71
Study 28768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataplexy
Number of subjects: 71
Study 28768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid PTSD
Number of subjects: 71
Study 28768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Older participants and those with higher aggression, anxiety or depression
Number of subjects: 71
Study 28768075 — intervention group
Group type: COMPARATOR
Intervention: mTBI
Number of subjects: 71
Study 28768075 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI÷PTSD
Number of subjects: 71
Study 28768072 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) assessment via 24-hour ambulatory electrocardiography; segments included sleep, wakefulness, exercise, standing still.
Number of subjects: 0
Study 28768072 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal Sharpened Romberg Test
Number of subjects: 0
Study 28768072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological nystagmus
Number of subjects: 0
Study 28768072 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sympathetic modulation
Number of subjects: 0
Study 28768072 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Pittsburgh Sleep Quality Index scores
Number of subjects: 0
Study 28768493 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive text messages (twice-daily for 3 months)
Number of subjects: 73
Study 28768493 — intervention group
Group type: COMPARATOR
Intervention: Control group (single text message every fortnight)
Number of subjects: 73
Study 28768612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based intervention (Fitbit Flex, online educational program, biweekly text messages)
Number of subjects: 40
Study 28768652 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut and peanut butter consumption
Number of subjects: 0
Study 28768652 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nut and peanut butter consumption)
Number of subjects: 0
Study 28768681 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM therapy
Number of subjects: 17
Study 28768756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg plus aspirin 325 mg (loading dose) followed by ticagrelor 90 mg BID plus aspirin 81 mg QD (maintenance therapy)
Number of subjects: 20
Study 28768756 — intervention group
Group type: COMPARATOR
Intervention: Concentrated platelets supplementation (0%, 25%, 50%, 75%)
Number of subjects: 20
Study 28768758 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Endothelial Shear Stress (ESS <1 Pa)
Number of subjects: 20
Study 28768758 — intervention group
Group type: COMPARATOR
Intervention: Higher Endothelial Shear Stress (ESS ≥1 Pa)
Number of subjects: 20
Study 28768758 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ESS
Number of subjects: 20
Study 28768799 — intervention group
Group type: EXPERIMENTAL
Intervention: SAH patients
Number of subjects: 37
Study 28768799 — intervention group
Group type: COMPARATOR
Intervention: Neurologically healthy patients
Number of subjects: 37
Study 28768822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (1.0 g/kg every 3 weeks for up to 52 weeks)
Number of subjects: 49
Study 28768847 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with sensory-motor polyneuropathy
Number of subjects: 160
Study 28768847 — intervention group
Group type: EXPERIMENTAL
Intervention: Older males
Number of subjects: 160
Study 28768847 — intervention group
Group type: EXPERIMENTAL
Intervention: Older females
Number of subjects: 160
Study 28768847 — intervention group
Group type: COMPARATOR
Intervention: Males and females
Number of subjects: 160
Study 28768906 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state (after 24 hours fasting)
Number of subjects: 23
Study 28768906 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiety state
Number of subjects: 23
Study 28768906 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological hunger
Number of subjects: 23
Study 28768906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin signaling
Number of subjects: 23
Study 28769925 — intervention group
Group type: EXPERIMENTAL
Intervention: RO5459072, a small molecule inhibitor of Cathepsin S
Number of subjects: 0
Study 28769925 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28769985 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment
Number of subjects: 505
Study 28770037 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaffected siblings of ASD probands (AS)
Number of subjects: 199
Study 28770037 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaffected siblings of AS probands
Number of subjects: 199
Study 28770037 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaffected siblings of autism probands
Number of subjects: 199
Study 28770037 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotyped behaviors
Number of subjects: 199
Study 28770037 — intervention group
Group type: COMPARATOR
Intervention: Typically developing controls (TD)
Number of subjects: 199
Study 28770094 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc protoporphyrin (ZPP) combined with haemoglobin concentration
Number of subjects: 338
Study 28770094 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc protoporphyrin (ZPP) alone
Number of subjects: 338
Study 28770094 — intervention group
Group type: COMPARATOR
Intervention: Haemoglobin concentration alone
Number of subjects: 338
Study 28770096 — intervention group
Group type: EXPERIMENTAL
Intervention: BELA-P-k questionnaire
Number of subjects: 202
Study 28770096 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson Disease Questionnaire -39 (PDQ39)
Number of subjects: 202
Study 28770096 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Parkinson's Disease Rating Scale (UPDRS)
Number of subjects: 202
Study 28770096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE)
Number of subjects: 202
Study 28770096 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Assessment Battery (FAB)
Number of subjects: 202
Study 28770108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac with local anesthesia
Number of subjects: 59
Study 28770108 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia alone (Control)
Number of subjects: 59
Study 28770254 — intervention group
Group type: EXPERIMENTAL
Intervention: FEMBraces
Number of subjects: 48
Study 28770254 — intervention group
Group type: COMPARATOR
Intervention: CtrlBraces
Number of subjects: 48
Study 28770322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 3234
Study 28770322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (masked)
Number of subjects: 3234
Study 28770322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3234
Study 28770322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (continued in DPPOS)
Number of subjects: 3234
Study 28770322 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 3234
Study 28770322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3234
Study 28770408 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (55 kBq/kg, intravenously) in a 4-week cycle for six cycles
Number of subjects: 49
Study 28770420 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF 240 mg twice daily
Number of subjects: 769
Study 28770420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769
Study 28770543 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality-based neurocognitive stimulation sessions (20-min daily sessions)
Number of subjects: 20
Study 28771388 — intervention group
Group type: EXPERIMENTAL
Intervention: Single unit porcelain-fused-to-metal (PFM) crowns (SCs)
Number of subjects: 120
Study 28771388 — intervention group
Group type: EXPERIMENTAL
Intervention: 3- to 4-unit PFM fixed dental prostheses (FDPs)
Number of subjects: 120
Study 28771392 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive battery of assessments for auditory and vestibular function
Number of subjects: 71
Study 28771673 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent lenalidomide
Number of subjects: 0
Study 28771673 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice single-agent therapy
Number of subjects: 0
Study 28771889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralatrexate, given i.v. weekly for 6 weeks of a 7-week cycle
Number of subjects: 0
Study 28771889 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent vitamin B, given alongside pralatrexate
Number of subjects: 0
Study 28772110 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensated Leydig cell dysfunction
Number of subjects: 158
Study 28772110 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncompensated Leydig cell dysfunction
Number of subjects: 158
Study 28772110 — intervention group
Group type: COMPARATOR
Intervention: Leydig cell dysfunction (both compensated and uncompensated)
Number of subjects: 158
Study 28772110 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone
Number of subjects: 158
Study 28772110 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinising hormone (LH)
Number of subjects: 158
Study 28772306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung adenocarcinoma treatment, specific intervention details not available.
Number of subjects: 0
Study 28772306 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific details not available.
Number of subjects: 0
Study 28774194 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for alcohol use disorder (family history of alcoholism, male sex, impulsivity)
Number of subjects: 159
Study 28774194 — intervention group
Group type: EXPERIMENTAL
Intervention: All three risk factors present
Number of subjects: 159
Study 28774271 — intervention group
Group type: EXPERIMENTAL
Intervention: Malay version of the Brief Illness Perception Questionnaire (MBIPQ)
Number of subjects: 312